3,000 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Cannon Global Investment Management LLC

Cannon Global Investment Management LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 3,000 shares of the medical research company’s stock, valued at approximately $475,000.

Several other institutional investors and hedge funds also recently modified their holdings of NTRA. Vanguard Group Inc. grew its position in Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock valued at $1,949,697,000 after buying an additional 879,463 shares in the last quarter. LPL Financial LLC boosted its holdings in shares of Natera by 33.7% in the fourth quarter. LPL Financial LLC now owns 80,332 shares of the medical research company’s stock valued at $12,717,000 after acquiring an additional 20,260 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Natera in the fourth quarter valued at approximately $3,768,000. Quantbot Technologies LP bought a new position in shares of Natera in the fourth quarter valued at approximately $878,000. Finally, Semanteon Capital Management LP boosted its holdings in shares of Natera by 25.6% in the fourth quarter. Semanteon Capital Management LP now owns 9,027 shares of the medical research company’s stock valued at $1,429,000 after acquiring an additional 1,840 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Stock Up 1.0 %

NTRA opened at $151.15 on Monday. The business has a 50 day moving average price of $161.23 and a 200 day moving average price of $150.01. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The firm has a market cap of $20.43 billion, a P/E ratio of -85.88 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on NTRA. The Goldman Sachs Group increased their price target on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, March 19th. JPMorgan Chase & Co. upped their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Finally, Sanford C. Bernstein increased their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 1,026 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total value of $149,837.04. Following the completion of the transaction, the insider now owns 144,782 shares of the company’s stock, valued at $21,143,963.28. This represents a 0.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the transaction, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 306,797 shares of company stock worth $48,940,883 over the last three months. 7.60% of the stock is currently owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.